An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia


Purpose: Dysplastic lesions of the oral epithelium are known precursors of oral cancer. A significant proportion of oral dysplastic lesions have functional defects in p53 response pathways. The ONYX-015 adenovirus is selectively cytotoxic to cells carrying defects in p53-dependent signaling pathways. The current study sought to establish the feasibility and activity of ONYX-015 administered topically as a mouthwash to patients with clinically apparent and histologically dysplastic lesions of the oral mucosa.

Patients and Methods: A total of 22 patients (19 assessable patients) were enrolled onto the study. ONYX-015 was administered on three different schedules to consecutive cohorts. Biopsies of the involved mucosa were performed to evaluate histologic response and changes in expression of putative markers of malignant potential, including p53, cyclin D1, and Ki-67. Serology was performed to measure antiadenoviral titers.

Results: Histologic resolution of dysplasia was seen in seven (37%) of 19 patients, and the grade of dysplasia improved in one additional patient. The majority of responses were transient. No toxicity greater than grade 2 (febrile episode in one patient) was observed. Only one of seven patients demonstrated an increase in circulating antiadenoviral antibody titers while on therapy. Although responding and resistant lesions had similar mean p53 staining at baseline, histologic response correlated with a decrease in p53 positivity over time. Significant changes in cyclin D1 or Ki-67 were not observed. Viral replication was confirmed in two of three lesions examined.

Conclusion: This novel approach to cancer prevention is tolerable, feasible, and has demonstrable activity.

© 2003 by American Society of Clinical Oncology.
findings suggest that mutational inactivation of p53 is a critical and relatively early event in oral carcinogenesis, often preceding clinically evident malignant transformation.

ONYX-015 is an attenuated adenovirus designed to preferentially replicate in and destroy p53-mutant cells.28-30 ONYX-015 carries an inactivating deletion in the gene encoding the E1B 55-kd protein. The E1B 55-kd protein binds to and inactivates cellular p53 and is required for efficient viral replication in most human cells.31 In cells lacking p53 function, adenoviral replication can proceed in the absence of E1B 55-kd protein. Thus, ONYX-015 may be selectively lytic in cells in which p53-dependent signaling pathways are nonfunctional.30

Recent studies demonstrate that ONYX-015 can replicate in several tumor lines containing intact p53, in contrast to initial expectations.32 Cell lines that support ONYX-015 replication despite normal p53 genotype seem to carry other defects in p53-dependent response pathways, including abnormal expression of MDM2 and p14ARF.33,34 These observations extend the potential antitumor activity of ONYX-015 to include not only cells with inactivating mutations of p53 but also cells harboring other functional defects in p53-dependent response pathways.

We hypothesized that topical application of ONYX-015 might have significant efficacy against oral dysplasia. Because dysplastic lesions are confined to the epithelial layer, cells within such lesions might be accessible by direct topical viral administration. The frequent association of oral dysplasia with disruption of p53 function would be expected to support productive replication of ONYX-015. Mouthwash delivery allows concurrent treatment of the entire oral mucosal field; cells harboring premalignant genetic alterations in areas not demonstrating grossly evident dysplasia might also be susceptible to viral infection and lysis. Finally, topical administration was predicted to limit potential adverse effects by minimizing systemic viral exposure, an important consideration in preventive therapy.

Based on these considerations, we initiated a clinical trial for patients with oral dysplasia using ONYX-015 in suspension as an oral rinse. The goals of this study included evaluation of toxicity and feasibility of viral mouthwash administration, quantitative analysis of histologic response in oral dysplasia, and investigation of potential associations between response and molecular determinants of hyperproliferation or transformation associated with oral cancer, including p53, Ki-67, and cyclin D1.35

PATIENTS AND METHODS

Patients

Enrollment was limited to adults (age ≥ 18 years) with a Zubrod performance status of 2 or less. Eligible patients had grossly evident oral leukoplakia or erythroplakia with histologic evidence of dysplasia on biopsy. All patients provided written informed consent before study enrollment or performance of study-related procedures, in accordance with institutional and federal guidelines.

Virus Administration

ONYX-015 was administered in a total volume of 15 mL of 5% dextrose and 0.45 N saline. Patients were asked to hold the viral suspension in their mouths for a duration of 30 minutes and then to expectorate any remaining solution.

Schedules of Administration

Cohorts of patients were treated on three different sequentially tested regimens (Fig 1). Cohort 1 (n = 7) consisted of patients who were administered ONYX-015 10^10 plaque forming units (pfu) daily for 5 days, with cycles repeated every 4 weeks for a maximum of 12 cycles. The rationale behind this schedule was to maximize viral infection over a week and to provide a treatment-free interval of 3 weeks to monitor for toxicity. Patients underwent lesion biopsy before initiation of therapy and during cycles 6 and 12. Cohort 2 (n = 12) were administered a similar dose-intensity, receiving once-weekly administration of ONYX-015 10^10 pfu for 24 weeks. Patients underwent biopsy before initiation of therapy and in week 12. Patients demonstrating a histologic response continued on therapy to week 24. Cohort 3 (n = 3) was designed to evaluate a more dose-intensive regimen and to combine the potentially beneficial aspects of both prior regimens. Patients in cohort 3 received ONYX-015 10^11 pfu daily for 5 days, followed by weekly administration over the next 5 weeks. This 6-week block was repeated in weeks 7 to 12.

Immunohistochemical Analyses

Biopsy samples were formalin-fixed and paraffin-embedded before sectioning (sections, 8 to 10 μm). Sections were deparaffinized and taken through a graded alcohol series. After heat-mediated antigen retrieval, slides were incubated in Tris 3% H2 O2 and incubated with primary antibodies at room temperature, including anti-p53 (Ab6, Oncogene Research Products, San Diego, CA), anti–Ki-67 (Ki-S; DAKO, Carpinteria, CA), and anticyclin D1 (antisera; Cell Marque, Austin, TX). After washing with buffer, slides were incubated with appropriate secondary antibodies, and antigen-antibody binding was detected using the 3,3′-diaminobenzidine substrate chromogen system. Slides were counterstained with hematoxylin. The immunohistochemical grading scale, which was performed by observers blinded to patient data and time of biopsy, was as follows: 0, 0% to 5% positive staining; 1, more than 5% to 20% positive; 2, more than 20% to 50% positive; or 3, more than 50% positive. Positivity of p53 was based on nuclear staining with the anti-p53 antibody.
In Situ Hybridization

Slides were deparaffinized in xylene and washed in ethanol. Slides were immersed in phosphate-buffered saline and Triton X-100, followed by proteinase K digestion and fixation in 4% paraformaldehyde. After dehydration through a series of ethanol washes (70% to 100%), slides were incubated overnight with Adenovirus BioProbe or negative control probe according to the manufacturer’s instructions (Enzo Life Sciences, Farmingdale, NY). Slides were washed and treated with antibiotin and alkaline phosphatase conjugate (Vector Laboratories, Burlingame, CA). The alkaline phosphatase substrate, 5-bromo-4-chloro-3-indolyl phosphate nitroblue tetrazolium salt, was applied, followed by counterstaining with nuclear fast red.

Statistical Methods

The changes over time in molecular correlates including p53, Ki-67, and cyclin D1 in responding and nonresponding patients were compared using the Wilcoxon rank-sum test and Spearman correlation.

RESULTS

Patient Characteristics

A total of 22 patients were enrolled onto this study. Patient characteristics are listed in Table 1. All patients treated had grossly evident abnormalities of the oral mucosa consisting of areas of leukoplakia, erythroplakia, or both. All patients were required to have mucosal dysplasia. Three patients in the first cohort were started on therapy based on pretreatment biopsies initially read by outside pathologists as demonstrating oral dysplasia that could not be confirmed by the study pathologists; two patients demonstrated mucosal hyperplasia without definitive dysplasia, and, in one patient, a focus of microinvasive carcinoma was noted. Because these three patients did not fulfill eligibility criteria, therapy was stopped after pathologic review, and these patients were excluded from analysis. In cohorts 2 and 3, pathologic confirmation of pretreatment dysplasia was performed by study pathologists before initiation of therapy (Table 2).

Patient Cohort 1

Four patients with initial biopsies demonstrating mucosal dysplasia were treated on this schedule. Two of four patients had histologic resolution of dysplasia after six cycles of viral therapy. One of these patients, who had a history of resected squamous cell carcinoma of the tongue and recurrent severe oral dysplasia and leukoplakia, experienced complete resolution of clinically evident disease after one cycle of therapy, associated with resolution of histologic dysplasia demonstrated on biopsy after cycle 6 (24 weeks, Fig 2). Despite no recurrence of leukoplakia or erythroplakia, a biopsy of normal-appearing mucosa after 12 cycles (48 weeks) demonstrated recurrent severe dysplasia. The other responding patient had a similar course, with resolution of histologic dysplasia after cycle 6 but recurrence and progression of disease after cycle 12.

Immunohistochemical staining for p53 paralleled response in the first of these two patients. The initial biopsy demonstrated...
strong p53 positivity that resolved after cycle 6 but recurred in conjunction with histologic dysplasia after cycle 12 (Fig 2). The dysplastic lesion of the second responding patient was negative for p53.

Cohorts 2 and 3

Because of the observed recurrence of disease in the responding patients in cohort 1, alternative schedules of administration were investigated. The rationale for adopting a weekly schedule for cohort 2 was to maintain similar dose-intensity to that given in cohort 1, while reducing the intervals between viral administrations from 3 weeks to 1 week. Cohort 3 was designed to evaluate the toxicity of a higher intensity regimen, combining aspects of both prior schedules.

Histologic responses were observed in both cohorts 2 and 3 (Table 3). Complete resolution of dysplasia was observed in four of 12 patients in cohort 2 and in one of three patients in cohort 3 (Fig 3). Partial response, from an initial histologic score of 3 to 1.5, was noted in one patient in cohort 2. Recurrent dysplasia after complete histologic response was noted in two patients, both in cohort 2; one of these responses was documented while on therapy (week 24), and the other was documented on first follow-up (week 48). Of the remaining two patients in cohort 2 with complete response, one was lost to follow-up after completing therapy, and one had no recurrent dysplasia on biopsy after 27 months. The patient with complete response in cohort 3 has also had no evidence of recurrence, with the most recent follow-up being 30 months after completion of therapy.

Toxicity

Administration of ONYX-015 as a mouthwash was well tolerated in all three cohorts (Table 4). Grade 1 diarrhea, possibly associated with therapy, was noted in four patients. A single episode of grade 2 toxicity was observed (cohort 2); an organ transplantation recipient with a history of recurrent oral herpes simplex virus lesions presented with fever, stomatitis, flu-like symptoms, and oral pain, all typical of previous herpes simplex virus recrudescence in this patient. These symptoms resolved over the course of 1 week, and the patient continued on therapy without further incident.

Systemic Exposure

One theoretical advantage of topical therapy for oral premalignant disease is avoidance of systemic exposure to cytotoxic therapy, thus potentially minimizing adverse effects. The lack of significant adverse effects attributable to the ONYX-015 therapy in this trial suggested that, in fact, such exposure was minimal. Systemic exposure of adenoviral vectors, including ONYX-015, is typically associated with an increase in circulating antadenoviral antibody titers. Circulating antadenoviral antibody titers were measured before therapy and after 12 weeks of therapy in seven patients in cohort 2. Only one of seven patients demonstrated any increase (two-fold) in antadenoviral titer over the course of treatment.

Molecular Correlates

All patients in cohorts 2 and 3 underwent mucosal biopsies before initiation and after 12 weeks of therapy for immunohistochemical and histologic evaluation. Mutation of the p53 gene can result in production of a stabilized dominant negative form, leading to marked increase in p53 protein levels detectable by immunohistochemistry. Constitutive overexpression of cyclin D1 has been strongly implicated in oral carcinogenesis. Ki-67, a marker of cellular proliferation, is frequently upregulated in oral cancer. Pretreatment staining indices for p53, cyclin D1, and
Ki-67, performed on biopsies from all patients in cohorts 2 and 3, were found to be indistinguishable in responding and nonresponding patients (Fig 4) and, thus, do not seem to be predictive of response to ONYX-015.

Although the pretreatment level of p53 expression did not differ between responding and nonresponding lesions, after 12 weeks of therapy, there was marked difference in p53 expression in responding versus nonresponding lesions; p53 level was significantly suppressed only in responding lesions (Fig 4). The change in p53 staining between responding and nonresponding patients was significant using the Wilcoxon rank-sum test ($P = .027$). Because both histologic change and p53 staining were measured on a graded scale, this association was further analyzed through derivation of a Spearman correlation ($r = .74$), confirming the association between histologic response and change in p53 ($P = .0017$). In contrast, no significant change in either cyclin D1 or Ki-67 expression was observed in responding or nonresponding patients on this study (Wilcoxon rank-sum test: for change in cyclin D1, $P = .74$; for change in Ki-67, $P = .82$).

**Viral Replication In Vivo**

Despite the clinical and histologic responses observed with this therapy, one concern was whether this attenuated adenovirus could actually gain access to and replicate within dysplastic mucosa when applied by topical oral administration. The three patients enrolled onto cohort 3, therefore, underwent an additional mucosal biopsy on day 8 of therapy. The goal of this early biopsy was to attempt to document productive ONYX-015 infection through detection of intracellular genome amplification by in situ hybridization; day 8 was expected to be early in the first round of productive viral synthesis. Scattered cells demonstrating strongly positive in situ hybridization throughout the cytoplasm were noted in biopsies of two of three patients, confirming the potential for productive ONYX-015 infection in oral dysplasia (Fig 5).

**DISCUSSION**

This trial explored three schedules of administration of a replication-competent adenovirus engineered for preferential replication in cells lacking functional p53-dependent response pathways. The rationale for this therapeutic approach was to selectively target a known signaling pathway implicated in oral carcinogenesis. The trial also explored the feasibility of topical oral administration of a chemopreventive agent as a mouthwash, treating the entire oral mucosa as a field and avoiding systemic toxicities in a preventive strategy. ONYX-015, administered as an oral rinse, was found to be extremely well tolerated at doses of up to $10^{11}$ pfu/d and was associated with complete histologic response in a subset of patients. Single daily doses of greater than $10^{11}$ pfu become impractical because of volume considerations. Given the lack of evident toxicity at even the highest dose evaluated, we recommend further exploration of activity based on the dose and schedule of cohort 3.
A significant negative correlation was observed between histologic response to ONYX-015 therapy and the fraction of cells with immunohistochemically detectable p53 protein. These data are consistent with the hypothesis that biologic response to ONYX-015 is dependent on the capacity to suppress or eliminate growth of p53 mutant cells. An alternative hypothesis could be that p53 staining correlates with histologic severity, regardless of response to therapy. However there was no apparent correlation between p53 staining and histologic severity in pretreatment biopsies. Prior studies of chemopreventive therapy for oral dysplasia have found no correlation between response and change in p53 expression.\textsuperscript{36} Furthermore, the two other biomarkers used in this study, cyclin D1 and Ki-67, have both been implicated in carcinogenic progression in oral cancer. In contrast to p53, no interval change in expression of either of these two markers was observed in responding or nonresponding patients. Thus, the correlation between change in biomarker expression levels and response to ONYX-015 was found exclusively for the abnormal p53 expression targeted by this agent. In addition to the immunohistochemical analysis used in this trial, incorporation of p53 gene sequencing in future trials involving ONYX-015 might provide further prognostic and mechanistic information.

Despite the observed histologic and clinical responses seen in this cohort of patients, this pilot trial cannot be taken as evidence of ONYX-015 efficacy for oral premalignancy. Although at least two patients remain without evidence of recurrence more than 2 years after therapy, the majority of responses were transient. The clinical course of oral dysplasia is variable and does include spontaneous regression of disease.\textsuperscript{14} The observed lack of improvement in cyclin D1 and Ki67 is of concern in this respect and suggests that not all genetic changes associated with premalignancy were reversed by ONYX-015 administration. Determination of response rate attributable to ONYX-015 will require a larger, randomized, phase II assessment.

Most chemoprevention trials for premalignant oral cavity lesions have been based on either naturally occurring compounds (vitamin A, vitamin E, and beta-carotene) or synthetically derived retinoids structurally related to vitamin A.\textsuperscript{37} Initial promising response rates reported with vitamin E and beta-carotene have not been consistently reproduced.\textsuperscript{38-40} The most extensively evaluated chemopreventive agent for oral cancer is isotretinoin, or 13-cis-retinoic acid.\textsuperscript{22-24,41,42} In a randomized, placebo-controlled study of high-dose isotretinoin in 44 patients with leukoplakia, both clinical and histologic response rates were significantly higher in the actively treated patients.\textsuperscript{29} Isotretinoin administration can be limited by toxicity, including both xeroderma and conjunctivitis, and responses are typically of short duration, with the majority of responding patients relapsing within 3 months. Progression of disease can be delayed but not prevented by continued administration of low-dose (0.5 mg/kg/d) isotretinoin.\textsuperscript{22,24}

Retinoid therapy has been evaluated in placebo-controlled trials as a chemopreventive agent in the context of localized head and neck cancer after therapy with curative intent. In the first of these trials, high-dose isotretinoin did not affect either locoregional or distant relapse rates relative to placebo, but it was associated with a reduction in the incidence of second primary tumors.\textsuperscript{41} A subsequent Eastern Cooperative Oncology Group trial evaluating low-dose isotretinoin versus placebo as secondary chemoprevention in 189 patients with a history of early-stage head and neck cancer failed to demonstrate an effect on the rates of relapse or second primary tumors.\textsuperscript{43} In both of these trials, toxicity was significantly higher in patients receiving isotretinoin therapy.

Topical administration of ONYX-015 for chemoprevention in the oral cavity has some theoretical advantages over systemic drug therapy. First, topical ONYX-015 administration limits exposure to the involved oral mucosa, minimizing the potential for adverse systemic effects. Second, this approach targets a signaling pathway implicated in malignant transformation. Unlike isotretinoin, which functions primarily as a differentiating agent, ONYX-015 has been shown to be selectively cytotoxic for cells with defects in p53-dependent response pathways. The lack of adverse effects with ONYX-015 combined with evidence of potential efficacy supports the rationale for phase II studies of this agent both in patients with oral dysplasia and as preventive therapy in patients at high risk of local relapse after resection of oral cancer.

Finally, ONYX-015 may have potential synergy with retinoid therapy in oral cancer chemoprevention. High-dose isotretinoin is primarily active against dysplastic lesions without upregulated p53 and does not suppress p53 levels in dysplasia.\textsuperscript{36} Through its differentiating activity, retinoid therapy may promote transient resolution of the hyperplastic and hyperkeratotic thickening of mucosa associated with early dysplastic lesions. Retinoid therapy might be predicted to increase the accessibility of the basal mucosal layers of dysplastic lesions to viral infection with ONYX-015. In addition to phase II studies of single-agent ONYX-015 in chemoprevention for oral cancer, analysis of the combined efficacy of the differentiating activity of retinoid therapies with the cytotoxic effect of ONYX-015 is warranted.

ACKNOWLEDGMENT
We thank Rosalyn Williams, Allison Dekker, and Anthea Atwell for data management and coordination of patient care, David Kim for contributions to initial trial design, Scott Freeman and Qing Wang for assistance with in situ hybridization, and Dezheng Huo for statistical analysis.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The authors indicated no potential conflicts of interest.

REFERENCES